Literature DB >> 19080742

Molecular profiling in glioblastoma: prelude to personalized treatment.

Nikol Mladkova1, Arnab Chakravarti.   

Abstract

The purpose of this review is to provide an up-to-date summary of the current knowledge and understanding of the molecular alterations and pathways relevant to the clinical outcome of glioblastoma patients and their potential use in designing personalized treatment for these patients. This article also discusses the potential of molecular profiling as a diagnostic modality, possible therapeutic implications of MGMT promoter methylation, the targeted inhibition of angiogenesis, and assessment of the tumor's molecular background with respect to PI3K/AKT pathway activation and associated molecules (EGFR, EGFRvIII, PTEN).

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19080742     DOI: 10.1007/s11912-009-0009-3

Source DB:  PubMed          Journal:  Curr Oncol Rep        ISSN: 1523-3790            Impact factor:   5.075


  36 in total

1.  Gene expression profiling of gliomas strongly predicts survival.

Authors:  William A Freije; F Edmundo Castro-Vargas; Zixing Fang; Steve Horvath; Timothy Cloughesy; Linda M Liau; Paul S Mischel; Stanley F Nelson
Journal:  Cancer Res       Date:  2004-09-15       Impact factor: 12.701

Review 2.  Impact of molecular profiling on clinical trial design for glioblastoma.

Authors:  Arnab Chakravarti; Erin Tyndall; Kamalakannan Palanichamy; Minesh Mehta; Kenneth Aldape; Jay Loeffler
Journal:  Curr Oncol Rep       Date:  2007-01       Impact factor: 5.075

Review 3.  Novel radiation-enhancing agents in malignant gliomas.

Authors:  Min Zhang; Arnab Chakravarti
Journal:  Semin Radiat Oncol       Date:  2006-01       Impact factor: 5.934

4.  Combination therapy of inhibitors of epidermal growth factor receptor/vascular endothelial growth factor receptor 2 (AEE788) and the mammalian target of rapamycin (RAD001) offers improved glioblastoma tumor growth inhibition.

Authors:  Ranjit K Goudar; Qing Shi; Mark D Hjelmeland; Stephen T Keir; Roger E McLendon; Carol J Wikstrand; Elizabeth D Reese; Charles A Conrad; Peter Traxler; Heidi A Lane; David A Reardon; Webster K Cavenee; Xiao-Fan Wang; Darell D Bigner; Henry S Friedman; Jeremy N Rich
Journal:  Mol Cancer Ther       Date:  2005-01       Impact factor: 6.261

5.  Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors.

Authors:  Ingo K Mellinghoff; Maria Y Wang; Igor Vivanco; Daphne A Haas-Kogan; Shaojun Zhu; Ederlyn Q Dia; Kan V Lu; Koji Yoshimoto; Julie H Y Huang; Dennis J Chute; Bridget L Riggs; Steve Horvath; Linda M Liau; Webster K Cavenee; P Nagesh Rao; Rameen Beroukhim; Timothy C Peck; Jeffrey C Lee; William R Sellers; David Stokoe; Michael Prados; Timothy F Cloughesy; Charles L Sawyers; Paul S Mischel
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

Review 6.  Genetic and hypoxic regulation of angiogenesis in gliomas.

Authors:  Balveen Kaur; Chalet Tan; Daniel J Brat; Dawn E Post; Erwin G Van Meir
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

7.  Survivin enhances radiation resistance in primary human glioblastoma cells via caspase-independent mechanisms.

Authors:  Arnab Chakravarti; Gary G Zhai; Min Zhang; Rajeev Malhotra; Douglas E Latham; Meaghan A Delaney; Pierre Robe; Ulf Nestler; Qinhui Song; Jay Loeffler
Journal:  Oncogene       Date:  2004-09-30       Impact factor: 9.867

8.  The added value of concurrently administered temozolomide versus adjuvant temozolomide alone in newly diagnosed glioblastoma.

Authors:  David J Sher; John W Henson; Bindu Avutu; Fred H Hochberg; Tracy T Batchelor; Robert L Martuza; Fred G Barker; Jay S Loeffler; Arnab Chakravarti
Journal:  J Neurooncol       Date:  2008-01-30       Impact factor: 4.130

Review 9.  Predictive and prognostic markers in neuro-oncology.

Authors:  Martin J van den Bent; Johan M Kros
Journal:  J Neuropathol Exp Neurol       Date:  2007-12       Impact factor: 3.685

Review 10.  Diagnosis and treatment of high-grade astrocytoma.

Authors:  Sith Sathornsumetee; Jeremy N Rich; David A Reardon
Journal:  Neurol Clin       Date:  2007-11       Impact factor: 3.806

View more
  6 in total

Review 1.  Integration and analysis of genome-scale data from gliomas.

Authors:  Gregory Riddick; Howard A Fine
Journal:  Nat Rev Neurol       Date:  2011-07-05       Impact factor: 42.937

2.  Glioblastoma blood flow measured with stable xenon CT indicates tumor necrosis, vascularity, and brain invasion.

Authors:  Matthew Crocker; Samira Saadoun; Alexa Jury; Chris Jones; Stergios Zacharoulis; Samiwel Thomas; Reyer Zwiggelaar; Leslie R Bridges; B Anthony Bell; Marios C Papadopoulos
Journal:  Neuro Oncol       Date:  2012-04-05       Impact factor: 12.300

Review 3.  Radiotherapy-drug combinations in the treatment of glioblastoma: a brief review.

Authors:  Patrick G McAleavey; Gerard M Walls; Anthony J Chalmers
Journal:  CNS Oncol       Date:  2022-05-23

4.  A high Notch pathway activation predicts response to γ secretase inhibitors in proneural subtype of glioma tumor-initiating cells.

Authors:  Norihiko Saito; Jun Fu; Siyuan Zheng; Jun Yao; Shuzhen Wang; Diane D Liu; Ying Yuan; Erik P Sulman; Frederick F Lang; Howard Colman; Roel G Verhaak; W K Alfred Yung; Dimpy Koul
Journal:  Stem Cells       Date:  2014-01       Impact factor: 6.277

5.  Synergistic drug combinations for a precision medicine approach to interstitial glioblastoma therapy.

Authors:  Elizabeth G Graham-Gurysh; Ananya B Murthy; Kathryn M Moore; Shawn D Hingtgen; Eric M Bachelder; Kristy M Ainslie
Journal:  J Control Release       Date:  2020-04-23       Impact factor: 9.776

6.  Glioblastoma-derived spheroid cultures as an experimental model for analysis of EGFR anomalies.

Authors:  Monika Witusik-Perkowska; Piotr Rieske; Krystyna Hułas-Bigoszewska; Magdalena Zakrzewska; Robert Stawski; Dominika Kulczycka-Wojdala; Michał Bieńkowski; Ewelina Stoczyńska-Fidelus; Sylwia M Grešner; Sylwester Piaskowski; Dariusz J Jaskólski; Wielisław Papierz; Krzysztof Zakrzewski; Maciej Kolasa; James W Ironside; Paweł P Liberski
Journal:  J Neurooncol       Date:  2010-08-29       Impact factor: 4.130

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.